EVAX – evaxion biotech a/s - american depositary share (US:NASDAQ)

News

Evaxion announces business update and full year 2025 financial results
Evaxion plans to file 2025 annual report later today
Evaxion to announce business update and full year 2025 financial results on March 5, 2026
Evaxion A/S (NASDAQ:EVAX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Evaxion expands AI-Immunology™ platform into autoimmune diseases
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com